Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro
Fierce Competition In Diabetes And Obesity Expected
New Phase II data shows combination of semaglutide plus a novel amylin analog outperforms semaglutide alone, and could surpass Lilly’s Mounjaro in helping weight loss in diabetes patients.
